AP-101 clinical trials

A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with familial amyotrophic lateral sclerosis (fALS) and sporadic amyotrophic lateral sclerosis (sALS)

This study is testing a new medicine, AP-101, for people with ALS. We want to see if it's safe and how the body handles it. Some people will get AP-101, others a dummy medicine, then everyone gets AP-101. It will help us understand more about ALS treatments.